Cargando…
Investigation of genotoxicity risk and DNA repair capacity in breast cancer patients using anastrozole
OBJECTIVE: Breast cancer is the most common cancer in women worldwide and the incidence increases in postmenopausal women. Anastrozole is a non-steroidal (type II), third-generation aromatase inhibitor (AI) that is used in the treatment of postmenopausal estrogen-related breast cancer. Several studi...
Autores principales: | Tugce Yesil, Devecioglu, Aydogan, Fatih, Omurtag, Gulden Zehra, Bese, Nuran Senel, Sardas, Semra |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Kare Publishing
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5864710/ https://www.ncbi.nlm.nih.gov/pubmed/29607425 http://dx.doi.org/10.14744/nci.2017.55822 |
Ejemplares similares
-
Male Breast Cancer: 37-Year Data Study at a Single Experience Center in Turkey
por: Selcukbiricik, Fatih, et al.
Publicado: (2013) -
Effects of psoralen on the pharmacokinetics of anastrozole in rats
por: Zhang, Yuzhu, et al.
Publicado: (2018) -
Fumonisins, Trichothecenes and Zearalenone in Cereals
por: Yazar, Selma, et al.
Publicado: (2008) -
Primary Gastric Lymphoma: Conservative Treatment Modality Is Not Inferior to Surgery for Early-Stage Disease
por: Selçukbiricik, Fatih, et al.
Publicado: (2012) -
Anastrozole (Arimidex ™) – an aromatase inhibitor for the adjuvant setting?
por: Buzdar, A U
Publicado: (2001)